Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Contineum Therapeutics (CTNM) Research & Development (2023 - 2025)

Contineum Therapeutics (CTNM) has 3 years of Research & Development data on record, last reported at $12.8 million in Q4 2025.

  • For Q4 2025, Research & Development fell 2.0% year-over-year to $12.8 million; the TTM value through Dec 2025 reached $51.5 million, up 34.1%, while the annual FY2025 figure was $51.5 million, 34.1% up from the prior year.
  • Research & Development reached $12.8 million in Q4 2025 per CTNM's latest filing, up from $11.0 million in the prior quarter.
  • Across five years, Research & Development topped out at $14.1 million in Q2 2025 and bottomed at $3.6 million in Q1 2023.
  • Average Research & Development over 3 years is $9.8 million, with a median of $9.6 million recorded in 2023.
  • The widest YoY moves for Research & Development: up 114.15% in 2024, down 16.48% in 2024.
  • A 3-year view of Research & Development shows it stood at $8.0 million in 2023, then soared by 62.44% to $13.0 million in 2024, then fell by 2.0% to $12.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Research & Development were $12.8 million in Q4 2025, $11.0 million in Q3 2025, and $14.1 million in Q2 2025.